Advanced

Role of biologics targeting type 2 airway inflammation in asthma : What have we learned so far?

Parulekar, Amit D.; Diamant, Zuzana LU and Hanania, Nicola A. (2017) In Current Opinion in Pulmonary Medicine 23(1). p.3-11
Abstract

Purpose of review Severe asthma is a heterogeneous syndrome that can be classified into distinct phenotypes and endotypes. In the type 2 (T2)-high endotype, multiple cytokines are produced that lead to eosinophilic inflammation. These cytokines and their receptors are targets for biologic therapies in patients with severe asthma who do not respond well to standard therapy with inhaled corticosteroids. Recent findings In the last decade, an increasing number of biologic therapies have been developed targeting T2 inflammation. Clinical trials of therapies targeting immunoglobulin E as well as the T2 cytokines interleukin (IL)-4, IL-5, and IL-13 have demonstrated that these treatments improve asthma-related clinical outcomes and/or have... (More)

Purpose of review Severe asthma is a heterogeneous syndrome that can be classified into distinct phenotypes and endotypes. In the type 2 (T2)-high endotype, multiple cytokines are produced that lead to eosinophilic inflammation. These cytokines and their receptors are targets for biologic therapies in patients with severe asthma who do not respond well to standard therapy with inhaled corticosteroids. Recent findings In the last decade, an increasing number of biologic therapies have been developed targeting T2 inflammation. Clinical trials of therapies targeting immunoglobulin E as well as the T2 cytokines interleukin (IL)-4, IL-5, and IL-13 have demonstrated that these treatments improve asthma-related clinical outcomes and/or have steroid-sparing properties. The use of biomarkers of T2 inflammation can help to identify the subset of patients in whom these therapies may be most efficacious. Multiple biologic agents that are directed at other targets are currently in development, including thymic stromal lymphopoietin (TSLP), prostaglandin (PG)D2 receptor, IL-25, and IL-33. Summary Biologics are emerging as a key component of severe asthma management. In patients with T2-high severe asthma, the addition of treatments targeting immunoglobulin E and IL-5 to standard therapy may lead to improvement in clinical outcomes. Other biologic therapies have shown promising preliminary results and need to be studied in further clinical trials. These biologic therapies in conjunction with biomarkers will lead to tailored therapy for asthma.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biologics, Immunoglobulin E, Interleukin 13, Interleukin 4, Interleukin 5, Severe asthma
in
Current Opinion in Pulmonary Medicine
volume
23
issue
1
pages
9 pages
publisher
Lippincott Williams & Wilkins
external identifiers
  • scopus:85007306396
  • wos:000390239200002
ISSN
1070-5287
DOI
10.1097/MCP.0000000000000343
language
English
LU publication?
yes
id
511c9f1d-43f8-4d15-b05a-7c8f20a5599e
date added to LUP
2017-01-16 09:49:16
date last changed
2018-01-07 11:45:10
@article{511c9f1d-43f8-4d15-b05a-7c8f20a5599e,
  abstract     = {<p>Purpose of review Severe asthma is a heterogeneous syndrome that can be classified into distinct phenotypes and endotypes. In the type 2 (T2)-high endotype, multiple cytokines are produced that lead to eosinophilic inflammation. These cytokines and their receptors are targets for biologic therapies in patients with severe asthma who do not respond well to standard therapy with inhaled corticosteroids. Recent findings In the last decade, an increasing number of biologic therapies have been developed targeting T2 inflammation. Clinical trials of therapies targeting immunoglobulin E as well as the T2 cytokines interleukin (IL)-4, IL-5, and IL-13 have demonstrated that these treatments improve asthma-related clinical outcomes and/or have steroid-sparing properties. The use of biomarkers of T2 inflammation can help to identify the subset of patients in whom these therapies may be most efficacious. Multiple biologic agents that are directed at other targets are currently in development, including thymic stromal lymphopoietin (TSLP), prostaglandin (PG)D2 receptor, IL-25, and IL-33. Summary Biologics are emerging as a key component of severe asthma management. In patients with T2-high severe asthma, the addition of treatments targeting immunoglobulin E and IL-5 to standard therapy may lead to improvement in clinical outcomes. Other biologic therapies have shown promising preliminary results and need to be studied in further clinical trials. These biologic therapies in conjunction with biomarkers will lead to tailored therapy for asthma.</p>},
  author       = {Parulekar, Amit D. and Diamant, Zuzana and Hanania, Nicola A.},
  issn         = {1070-5287},
  keyword      = {Biologics,Immunoglobulin E,Interleukin 13,Interleukin 4,Interleukin 5,Severe asthma},
  language     = {eng},
  number       = {1},
  pages        = {3--11},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Current Opinion in Pulmonary Medicine},
  title        = {Role of biologics targeting type 2 airway inflammation in asthma : What have we learned so far?},
  url          = {http://dx.doi.org/10.1097/MCP.0000000000000343},
  volume       = {23},
  year         = {2017},
}